Surrozen gets FDA IND clearance for diabetic macular edema treatment SZN-8141
Surrozen, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SZN-8141, a potential treatment for diabetic macular edema. The first patient is expected to be dosed in the DUET study in the fourth quarter of 2026.